Retatrutide vs Tirzepatide: Triple vs Dual Agonist — Structure, Half-Life, Trial Data

By The Peptides Codex Editorial TeamReviewed September 7, 2026

The short version

Tirzepatide activates two receptors (GIP and GLP-1) and has been approved since 2022. Retatrutide activates three (GIP, GLP-1 and glucagon) and is still in phase 3, with a US filing planned for early 2027. Both are 39-amino-acid peptides from Eli Lilly built on the same GIP-derived backbone with an exendin-4 tail and a C20 fatty diacid. Retatrutide's phase 2 obesity trial reported −24.2% body weight at 48 weeks; tirzepatide's SURMOUNT-1 reported −20.9% at 72 weeks. Those numbers come from different trials with different populations and durations, and there is no head-to-head comparison.

Structure: what actually differs

Set the two sequences side by side and they share the N-terminal tyrosine, the Aib at position 2, the GIP-like core and the identical C-terminal tail G-G-P-S-S-G-A-P-P-P-S-NH2. Retatrutide swaps glutamate for glutamine at position 3, replaces Aib13 with α-methyl-leucine, adds a second Aib at position 20, changes several residues between 16 and 28, and moves the fatty diacid from lysine 20 to lysine 17 with one OEG spacer instead of two. Those mid-chain changes are what unlock glucagon receptor activity. The verified formulas are C225H348N48O68 (tirzepatide, ≈4,814 Da) and C221H342N46O68 (retatrutide, ≈4,731 Da).

Verified structural comparison
Feature	Tirzepatide	Retatrutide
Length	39 aa	39 aa
Scaffold	GIP core + exendin-4 tail	GIP core + exendin-4 tail
Non-canonical residues	Aib2, Aib13	Aib2, αMeLeu13, Aib20
Acylation	Lys20 · C20 diacid-γGlu-2×OEG	Lys17 · C20 diacid-γGlu-OEG
Formula / mass	C225H348N48O68 / ≈ 4,814 Da	C221H342N46O68 / ≈ 4,731 Da
Receptors	GIPR + GLP-1R	GIPR + GLP-1R + GCGR
Half-life	≈ 5 days	≈ 6 days
Status (Sept 2026)	Approved (Mounjaro, Zepbound)	Investigational, phase 3

Receptor pharmacology: what the third receptor adds

Both molecules are GIPR-favouring by design, with GLP-1 receptor activity somewhat below native GLP-1. The glucagon receptor is the difference. Glucagon agonism raises energy expenditure and drives fat oxidation in the liver, which is the mechanistic argument for retatrutide's larger weight loss and its striking liver-fat reductions in the MASLD substudy. It also raises glucose and heart rate, so the potency ratio had to be set so that the incretin components dominate; the phase 2 diabetes trial confirmed that glucose fell rather than rose. Tirzepatide has no glucagon receptor activity and therefore neither the benefit nor the constraint.

Half-life and dosing cadence

Tirzepatide's half-life is about 5 days (≈117 hours); retatrutide's is about 6 days. Both are dosed once weekly with stepwise escalation to limit gastrointestinal side effects. Tirzepatide's approved schedule starts at 2.5 mg and rises in 2.5 mg steps to a maximum of 15 mg. Retatrutide's trials started at 2 mg (or 4 mg) and escalated to maintenance doses of 4, 8, 9 or 12 mg depending on the study; the lower 2 mg start reduced early nausea. Neither should be read as a protocol — the dosing guide lists exactly which arms each published trial used.

Weight-loss data, side by side (different trials)

In SURMOUNT-1 (2,539 adults with obesity, 72 weeks), tirzepatide 5, 10 and 15 mg produced −15.0%, −19.5% and −20.9% versus −3.1% with placebo. In retatrutide's phase 2 (338 adults, 48 weeks), 4, 8 and 12 mg produced −17.1%, −22.8% and −24.2% versus −2.1%, and weight was still falling at the end. Retatrutide's phase 3 TRANSCEND-T2D-1 (type 2 diabetes, 40 weeks) reported −11.5% to −15.3%, which — like tirzepatide's SURPASS numbers — is lower than in people without diabetes. The only firm conclusion is that both produce weight loss well beyond single-agonist GLP-1 drugs; the size of any difference between them awaits a direct comparison.

Cross-trial comparison — indicative only
Trial	Drug / dose	Population	Duration	Weight change
SURMOUNT-1 (2022)	Tirzepatide 15 mg	Obesity, no diabetes	72 weeks	−20.9% (placebo −3.1%)
Phase 2 obesity (2023)	Retatrutide 12 mg	Obesity, no diabetes	48 weeks	−24.2% (placebo −2.1%)
SURPASS-2 (2021)	Tirzepatide 15 mg	Type 2 diabetes	40 weeks	≈ −11 kg
TRANSCEND-T2D-1 (2026)	Retatrutide 12 mg	Type 2 diabetes	40 weeks	−15.3% (placebo −2.6%)

Side effects: same class, two additions

Both produce dose-related gastrointestinal events — nausea, diarrhoea, vomiting, constipation — that are mostly mild to moderate and cluster during escalation. Retatrutide adds two signals plausibly linked to glucagon agonism: a dose-dependent rise in heart rate that peaked around 24 weeks and then declined, and skin sensitivity (dysesthesia) reported more often than placebo at higher doses. Tirzepatide has years of post-marketing data and completed cardiovascular outcome trials; retatrutide's TRIUMPH-Outcomes trial is ongoing. The retatrutide side-effects guide goes through the published data in detail.

Approval status and what it means for readers

Tirzepatide is an approved prescription medicine (Mounjaro for type 2 diabetes, Zepbound for weight management and obstructive sleep apnoea) manufactured under pharmaceutical GMP. Retatrutide is not approved anywhere as of September 2026: it exists only in clinical trials and, since August 2026, in Lilly's pre-approval expanded-access programme. Everything sold online as retatrutide is unlicensed material of unverified content. That asymmetry — one drug with a label, safety database and quality system, one without — matters more than any cross-trial percentage.

Sources and what they cover

These primary studies, official records and standards cover the topics linked below. The scope notes distinguish laboratory findings, human trials and regulatory records. This is a selected bibliography, not a systematic review or verification of every sentence; absence of a study here does not prove that no study exists.

Willard et al. (2020) — Tirzepatide as an imbalanced, biased dual receptor agonist
Primary receptor pharmacology and molecular design; not itself a clinical outcomes trial.
Relevant sections: Structure: what actually differs · Receptor pharmacology: what the third receptor adds
Li et al. (2024) — Structural basis of retatrutide triple-receptor agonism
Structural receptor research; biological plausibility is separate from proven clinical benefit.
Relevant sections: Structure: what actually differs · Receptor pharmacology: what the third receptor adds
Jastreboff et al. (2022) — SURMOUNT-1: tirzepatide for obesity
Randomized obesity trial; not a direct comparison with retatrutide.
Relevant sections: Weight-loss data, side by side (different trials)
Jastreboff et al. (2023) — Retatrutide for obesity, phase 2 trial
Phase 2 obesity trial: studied regimens, weight and adverse events. Trial doses are not instructions for personal use.
Relevant sections: Weight-loss data, side by side (different trials) · Side effects: same class, two additions

FAQ

What is the difference between retatrutide and tirzepatide?+

Tirzepatide activates the GIP and GLP-1 receptors; retatrutide activates those two plus the glucagon receptor. They share the same 39-residue GIP-based architecture, differing in a handful of mid-chain residues and the acylation site (Lys20 vs Lys17).

Which is stronger, retatrutide or tirzepatide?+

No head-to-head trial exists. In separate studies retatrutide reached −24.2% at 48 weeks (phase 2) and tirzepatide −20.9% at 72 weeks (SURMOUNT-1). Different populations, durations and dose schedules make this indicative only.

Is retatrutide approved like tirzepatide?+

No. Tirzepatide has been approved since 2022. Retatrutide is investigational; Lilly plans to file with the FDA in early 2027.

Is retatrutide just tirzepatide with a longer half-life?+

No. The half-lives are similar (≈6 vs ≈5 days). The real difference is glucagon receptor activity, which changes both efficacy and the side-effect profile.

Can you switch between them?+

That is a clinical question for a prescriber, and outside the scope of an educational site. Retatrutide is not available outside trials and expanded access in any case.